Stock Evaluator: Xvivo Perfusion AB (publ) (XVIPY)
Xvivo Perfusion AB (publ) XVIPY
$6.88
0.00
0.00%
September 2, 2026 10:46:55 AM
EST
Volume: 0
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Financial Summary
| Share Statistics | XVIPY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $866.2 | $423.7 | 43% |
|
| Shares Out (Mil) | 3.3 | 41.5 | 11% |
|
| Institutional Ownership | 49.6% | 83.6% | 24% |
|
| Float (Mil) | 25.1 | 35.5 | 33% |
|
| Beta | 1.46 | 0.88 | 81% |
|
| Avg Daily Volume (000s) | 1 | 336 | 4% |
|
| Price Change (52-week) |
na | 65.2% | na |
|
| Growth | XVIPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 32.1% | 11.8% | 91% |
|
| Net Income (5yr) | 20.2% | (5.8%) | 73% |
|
| EPS (5yr) | 19.6% | 10.4% | 67 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.6%) | (15.5%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XVIPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $92 | $119 | 25% |
|
| Net Income (TTM) (Mil) | $9 | ($9) | 45% |
|
| EPS (TTM) | $0.290 | ($0.400) | 49% |
|
| Operating Cash Flow (TTM) (Mil) | $24 | ($3) | 42% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $1 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $23 | 29% |
|
| Enterprise Value (Q1) (Mil) | $757 | $376 | 38% |
|
| Valuation | XVIPY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.87 | na |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | XVIPY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 72.3% | 58.5% | 83% |
|
| Net Margin | 9.9% | (6.9%) | 62% |
|
| ROA | 3.6% | (13.3%) | 65% |
|
| ROE | 4.1% | (13.3%) | 42% |
|
| Liabilities to Assets | 12.9% | 46.2% | 8% |
|
| F-Score | na | 4 | na |
|
Xvivo Perfusion AB (publ) did not pass any screens on 9/3/2026.